medin-NC3 is the first turbine-driven CPAP device for non-invasive respiratory support for premature infants and newborns. The high-performance turbine makes the device independent of a fixed compressed air supply.
The proven MediTRIG technology is used in the ApneaCPAP mode. Powerful leakage compensation offsets leakages to ensure stable and effective therapy.
The device offers all basic modes for modern non-invasive respiratory support.
Die nCPAP-Modi sind so ausgelegt, dass Sie nur den gewünschten CPAP-Druck einstellen müssen. Der Flow wird dann abhängig vom Patientenzustand und allfälligen Leckagen angepasst. Dies verhindert unerwünschte Spitzendrücke, garantiert eine hoch effiziente Leckagekompensation und trägt zur Senkung des Sauerstoffverbrauchs bei. Dank hoher Messsensitivität erfolgt die Anpassung des Flows sehr rasch.
Apnea is detected by MediTRIG. As a result, breaths are automatically triggered to stimulate breathing. Frequency, pressure level and breath duration can be individually adjusted.
In addition to the PEEP, breaths with fixed settings (pressure level, duration, frequency) are administered. These breaths have a higher pressure level and are not emitted in a synchronized manner.
nHFT describes the supply of heated and humidified breathing gas via a nasal cannula. The gas flow administered is thus higher than the patient’s inspiratory respiratory flow. In neonatology, a flow of more than 1 LPM is considered to be high-flow therapy, while for adults, correspondingly higher values should be applied.
The MediTRIG respiratory trigger was specially developed by medin for use in premature infants and newborns. Through the combination of the pressure measurement in the Medijet® generator and the signal processing in the medin nCPAP devices, MediTRIG works without additional sensors.
MediTRIG detects central as well as obstructive apnea.
The high-performance turbine makes medin-NC3 independent of a fixed compressed air supply.
